What is "EULAR Recommendations for the Management of Behçet's Syndrome (2025 Update)"?
The EULAR Recommendations for the Management of Behçet's Syndrome: 2025 Update provide evidence-based guidance for diagnosing and treating Behçet's syndrome according to organ involvement. The guideline is intended for rheumatologists, ophthalmologists, dermatologists, internists, neurologists, gastroenterologists, trainees, and other healthcare professionals involved in multidisciplinary patient care.
Introduction
Behçet's syndrome is a complex multisystem inflammatory disease characterized by a relapsing-remitting course and the potential to affect virtually every organ system. Because disease manifestations range from recurrent oral ulcers to vision-threatening uveitis, vascular disease, neurological involvement, and gastrointestinal complications, treatment decisions must be individualized according to disease severity, affected organs, and patient-specific risk factors.
The EULAR Recommendations for the Management of Behçet's Syndrome: 2025 Update represent the latest consensus developed by an international multidisciplinary task force under the European Alliance of Associations for Rheumatology (EULAR). These updated recommendations integrate new evidence from randomized controlled trials, observational studies, and expert consensus to provide practical guidance for clinicians caring for patients with Behçet's syndrome.
Unlike traditional textbooks, this publication functions as an evidence-based clinical practice guideline. Rather than discussing disease mechanisms in depth, it focuses on treatment strategies, clinical decision-making, remission induction, maintenance therapy, and individualized management according to organ involvement.
For rheumatologists, ophthalmologists, dermatologists, neurologists, gastroenterologists, internists, residents, fellows, and other healthcare professionals, this guideline serves as an important reference for modern clinical practice.
Book Overview
|
Item |
Details |
|
Title |
EULAR Recommendations for the
Management of Behçet's Syndrome: 2025 Update |
|
Publication
Type |
Evidence-based Clinical Practice
Guideline |
|
Lead
Authors |
Gulen Hatemi, Sofia Ramiro, Yesim
Ozguler, Sinem Nihal Esatoglu, Gunnar Tomasson, and an international EULAR
task force |
|
Journal |
Annals of the Rheumatic Diseases |
|
Publication
Year |
2026 |
|
DOI |
10.1016/j.ard.2026.02.009 |
|
Medical
Specialty |
Rheumatology / Internal Medicine /
Multidisciplinary Autoimmune Disease Management |
|
Primary
Audience |
Rheumatologists, internists,
ophthalmologists, dermatologists, neurologists, gastroenterologists,
healthcare professionals, trainees, and patients with Behçet's syndrome |
What This Guideline Covers
A comprehensive evidence-based approach
The guideline updates previous EULAR recommendations using systematic literature reviews, expert consensus, and recently published clinical evidence. The task force reviewed studies published through November 2024 and developed recommendations following updated EULAR methodology.
The recommendations are organized according to organ involvement, reflecting the heterogeneous clinical presentation of Behçet's syndrome.
Major clinical domains include:
- General principles of disease management
- Mucocutaneous manifestations
- Joint involvement
- Ocular disease
- Arterial disease
- Venous thrombosis
- Gastrointestinal involvement
- Neurological disease
- Quality indicators
- Future research priorities
Overarching principles of management
A major strength of the guideline is its emphasis on five overarching principles that underpin all treatment decisions.
These principles emphasize that Behçet's syndrome:
- follows a relapsing-remitting course;
- may become organ- or life-threatening;
- requires prevention of irreversible organ damage;
- should be managed according to disease activity and prognostic factors;
- benefits from multidisciplinary care, patient education, and shared decision-making.
The guideline also highlights that treatment should be individualized according to:
- age,
- sex,
- disease duration,
- affected organs,
- disease severity,
- patient preferences.
Evidence-Based Management of Mucocutaneous Disease
The guideline recommends colchicine as first-line therapy for recurrent mucocutaneous lesions because of its efficacy, tolerability, and affordability.
For patients whose disease remains active despite colchicine or who cannot tolerate it, the guideline recommends considering:
- apremilast
- TNF-α inhibitors
Topical glucocorticoids remain useful for oral and genital ulcers, while prolonged systemic glucocorticoid therapy is discouraged for isolated mucocutaneous disease because of long-term adverse effects.
The document also discusses additional therapeutic agents—including azathioprine, interferon-alpha (noting limited availability), ustekinumab, thalidomide, and dapsone—while clearly explaining the quality of supporting evidence and why some therapies are not preferred in routine practice.
Joint Involvement
For Behçet-related arthritis, colchicine continues to be recommended as first-line treatment.
In recurrent or chronic arthritis, immunosuppressive therapy may be considered. The guideline also discusses options such as azathioprine, TNF-α inhibitors, apremilast, glucocorticoids, intra-articular injections, and NSAIDs depending on the clinical scenario and available evidence.
Eye Disease: Protecting Vision
One of the most clinically important sections addresses Behçet uveitis.
The guideline emphasizes that:
- all patients with Behçet uveitis require immunosuppressive therapy;
- glucocorticoids should not be used as monotherapy;
- patients with sight-threatening posterior uveitis should receive early treatment with monoclonal TNF-α antibodies, with infliximab preferred in combination with other immunosuppressive agents for severe posterior disease.
The document further discusses:
- angiographic remission,
- monitoring strategies,
- long-term maintenance,
- biologic therapy,
- combination therapy,
- areas where additional evidence is still needed.
Key Features
- Evidence-based recommendations developed using updated EULAR methodology.
- Recommendations organized according to organ involvement.
- Based on systematic literature reviews and expert consensus.
- Includes five overarching treatment principles.
- Covers both remission induction and long-term maintenance strategies.
- Incorporates recently published randomized controlled trials and observational studies.
- Highlights multidisciplinary management.
- Addresses quality of life alongside disease control.
- Discusses quality indicators for healthcare delivery.
- Identifies important priorities for future clinical research.
Who Should Read This Guideline?
This publication is particularly valuable for:
Rheumatologists
It provides comprehensive evidence-based treatment recommendations across the spectrum of Behçet's syndrome.
Internal Medicine Physicians
Internists caring for patients with multisystem inflammatory diseases will benefit from its organ-specific management strategies.
Ophthalmologists
The dedicated section on Behçet uveitis provides practical recommendations for preventing irreversible visual loss.
Dermatologists
Useful for managing recurrent oral ulcers, genital ulcers, papulopustular lesions, and other mucocutaneous manifestations.
Neurologists
Includes updated recommendations for parenchymal neurological disease and cerebral venous sinus thrombosis.
Gastroenterologists
Provides guidance on gastrointestinal Behçet disease, including diagnostic endoscopy and medical therapy.
Residents and Fellows
An excellent summary of contemporary evidence-based clinical management.
Medical Educators
Useful as a teaching resource illustrating evidence-based guideline development and multidisciplinary care.
Why This Guideline Is Useful
One of the greatest strengths of the EULAR Recommendations for the Management of Behçet's Syndrome: 2025 Update is its practical, organ-based approach to treatment.
Rather than recommending a single therapeutic pathway for all patients, the guideline recognizes the heterogeneous nature of Behçet's syndrome and emphasizes individualized treatment according to disease manifestations, prognostic factors, and patient preferences.
Strong Evidence-Based Foundation
The recommendations were developed using updated EULAR standard operating procedures and are supported by systematic literature reviews covering studies published through November 2024.
Evidence was assessed using established methodological frameworks, and recommendations were refined through expert consensus involving an international multidisciplinary task force.
Clinically Practical
The guideline provides practical recommendations for:
- First-line therapy
- Escalation strategies
- Biologic treatment
- Glucocorticoid use
- Maintenance therapy
- Monitoring
- Organ-specific management
- Shared decision-making
This practical orientation makes it valuable for day-to-day clinical care rather than serving solely as an academic reference.
Focus on Organ Preservation
A recurring theme throughout the guideline is preventing irreversible organ damage. Early recognition of severe disease and prompt initiation of effective immunosuppressive therapy are emphasized, particularly for ocular, vascular, neurological, and gastrointestinal involvement.
Table of Contents Overview
Based on the uploaded guideline, the major sections include:
- Introduction
- Methods
- Results
- Overarching Principles
Recommendations for:
- Mucocutaneous involvement
- Joint involvement
- Eye involvement
- Arterial involvement
- Venous thrombosis
- Gastrointestinal involvement
- Parenchymal nervous system involvement
- Quality Indicators
- Research Agenda
- Discussion
- References
Strengths of the Guideline
Several characteristics make this publication particularly valuable for clinicians.
Evidence-Based Recommendations
The recommendations integrate systematic literature reviews with expert consensus and assign levels of evidence and agreement to each recommendation, helping clinicians understand the strength of supporting data.
Multidisciplinary Perspective
The task force included rheumatologists, ophthalmologists, dermatologists, gastroenterologists, neurologists, health professionals, and patient research partners, reflecting the multisystem nature of Behçet's syndrome.
Organ-Specific Treatment Strategy
Management recommendations are organized according to organ involvement, allowing clinicians to quickly locate guidance relevant to specific clinical scenarios.
Incorporation of New Evidence
Compared with earlier versions, the update incorporates newer randomized trials, comparative studies, and observational evidence, including changes supporting earlier use of monoclonal TNF-α inhibitors for selected organ-threatening disease.
Practical Clinical Guidance
The document addresses treatment selection, monitoring, remission induction, maintenance therapy, and quality-of-care considerations, making it directly applicable to clinical practice.
Limitations
- High-quality randomized evidence remains limited for some therapies.
- Certain recommendations rely on observational studies with higher risk of bias.
- More prospective trials are needed to determine optimal treatment strategies, monitoring approaches, and tapering of immunosuppressive therapy.
- Evidence comparing biosimilars in Behçet's syndrome is currently lacking.
- Several research questions remain unanswered and are included in the guideline's proposed research agenda.
Comparison With Similar Publications
This guideline builds upon previous EULAR recommendations published in 2008 and updated in 2018. According to the authors, the 2025 update incorporates newer clinical evidence and includes one new recommendation, seven modified recommendations, and revised wording for four additional recommendations.
Major updates include stronger support for earlier use of monoclonal TNF-α inhibitors in selected patients with ocular, vascular, and nervous system involvement.
EULAR Recommendations for the Management of Behçet's Syndrome (2025 Update)
Or: Link 2
FAQs
It is an evidence-based clinical practice guideline developed by an international EULAR task force to provide recommendations for managing Behçet's syndrome according to organ involvement and current evidence.
The guideline is intended for physicians and healthcare professionals involved in the care of patients with Behçet's syndrome, including rheumatologists, ophthalmologists, dermatologists, gastroenterologists, neurologists, trainees, and patient organizations.
The recommendations emphasize individualized treatment based on organ involvement, disease activity, prognostic factors, multidisciplinary care, patient education, and prevention of irreversible organ damage.
They are organized according to the specific organs affected, including mucocutaneous, joint, ocular, vascular, gastrointestinal, and neurological involvement.
The update incorporates newer clinical evidence, modifies several previous recommendations, introduces one new recommendation, and supports earlier use of monoclonal TNF-α inhibitors in selected patients with major organ involvement.
Yes. It includes a dedicated research agenda identifying evidence gaps and areas where further prospective studies are needed.
Conclusion
The EULAR Recommendations for the Management of Behçet's Syndrome: 2025 Update provide a comprehensive, evidence-based framework for the management of this complex multisystem vasculitis. By organizing recommendations according to organ involvement and integrating systematic evidence with expert consensus, the guideline offers practical direction for clinicians caring for patients with Behçet's syndrome.
Its emphasis on individualized therapy, multidisciplinary collaboration, early recognition of severe disease, and prevention of irreversible organ damage reflects contemporary standards of care. For healthcare professionals seeking current guidance on diagnosis, treatment selection, and long-term management, this publication is an authoritative resource grounded in the latest available evidence.
Disclaimer
MedBook 4 Free does not own copyrights to this video/book/software. We’re sharing this with our audience ONLY for educational purposes, and we highly encourage our visitors to purchase original licensed software/books.
If someone with copyrights wants us to remove this software/book, please contact us immediately. You can send an email to [email protected] for all DMCA / removal requests.